Extended Data Fig. 2: Quality assessment of proteomic data and genomic landscape of HBV-related early-stage HCC. | Nature

Extended Data Fig. 2: Quality assessment of proteomic data and genomic landscape of HBV-related early-stage HCC.

From: Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

Extended Data Fig. 2

a, Distribution of log2-transformed iBAQ abundance of identified proteins in 199 proteome samples that passed quality control. Green presents non-tumour samples (n = 98), red denotes tumour samples (n = 101). In the box plots, the middle bar represents the median, and the box represents the interquartile range; bars extend to 1.5× the interquartile range. b, Cumulative number of protein identifications. Blue presents non-tumour samples (n = 98), red denotes tumour samples (n = 101). c, Cumulative number of phosphorylation site identifications. Blue presents non-tumour samples (n = 103), red denotes tumour samples (n = 103). d, The genomic landscape and mutational signatures in HBV-related early-stage HCC. Top, individual tumour mutation rates. Middle, AFP and MVI status of the 93 patients with HCC. Bottom, recurrently mutated genes. Mutation types are indicated in the legend at the bottom. The bar plot on the left shows the number of alterations for each gene in the 93 patients.

Source data

Back to article page